Long-acting injectable drug prevents HIV among men and transgender women
On May 18, 2020, an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks…
Global study tested malaria drug to protect health workers from COVID-19
On May 18, 2020, with $9 million from the COVID-19 Therapeutics Accelerator, an international group of physicians and…
CIRM board approved clinical trials targeting COVID-19 and sickle cell disease
On May 15, 2020, the California Institute for Regenerative Medicine (CIRM) board approved new clinical trials for COVID-19…
NIH began clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
On May 14, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that a clinical trial…
Immunic received regulatory approval from German Health Authority BfArM to initiate phase 2 clinical trial in COVID-19 patients
On May 13, 2020, Immunic announced it had received first regulatory approval from Germany’s BfArM to initiate a…
National Research Council of Canada and CanSino Biologics announced collaboration to advance vaccine against COVID-19
On May 12, 2020, the National Research Council of Canada (NRC) announced a collaboration with CanSino Biologics to…
The FDA announced actions to accelerate development of novel prevention, treatment options for COVID-19
On May 11, 2020, the FDA announced actions to accelerate the development of prevention and treatment options for…
Arbutus Biopharma announced research initiative to identify novel antiviral therapies for treatment of Coronavirus infections
On May 11, 2020, Arbutus Biopharma announced the establishment of a new research initiative focused on the identification…
NIH clinical trial testing antiviral remdesivir plus antiiInflammatory drug baricitinib for COVID-19 began
On May 8, 2020, the NIH announced that a randomized, controlled clinical trial evaluating the safety and efficacy…
Catalent partnered with Humanigen to support FDA approved phase 3 lenzilumab study for COVID-19
On May 7, 2020, Catalent announced Phase 3 study for lenzilumab, the companyﾒs proprietary Humaneeredﾮ anti-human granulocyte macrophage-colony…
Predictive Oncology launched new AI platform for vaccine and drug development targeting coronaviruses and Acute Respiratory Syndromes
On May 6, 2020, Predictive Oncology announced the acquisition of Soluble Therapeutics and partnership and licensing of a…
TGen and HonorHealth initiated COVID-19 combination therapy of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection
On May 5, 2020, the HonorHealth Research Institute and HonorHealth announced the successful enrollment on a novel combination…
Organicell announces FDA approval of IND application for treatment of SARS due to COVID-19
On May 5, 2020, Organicell Regenerative Medicine announced the FDA has approved the Investigational New Drug application for…
Pfizer and BioNTech dosed first participants in US as part of global COVID-19 mRNA vaccine development program
On May 5, 2020, Pfizer and BioNTech announced the first participants have been dosed in the U.S. in…
FDA issued Emergency Use Authorization for potential COVID-19 treatment
On May 1, 2020, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir…
US Dept of Veterans Affairs participated in drug, plasma trials in fight against COVID-19
On May 1, 2020, the U.S. Dept. of Veterans Affairs (VA) announced participation in a series of clinical…
NIH clinical trial shows remdesivir accelerated recovery from advanced COVID-19
On Apr. 29, 2020, the National Institutes of Health (NIH) announced that hospitalized patients with advanced COVID-19 and…
Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research
On Apr. 29, 2020, an anti-inflammatory drug developed at Scripps Research 25 years ago tested as a way…
Emory University helped lead research on drug to treat COVID-19 patients
On Apr. 29, 2020, Emory University played a leading role in the government-sponsored clinical trial of the COVID-19…
Clinical trial began to see if convalescent plasma can treat COVID-19
On Apr. 29, 2020, researchers at Montefiore Health System and Albert Einstein College of Medicine and NYU Langone…
Clinical trial of drug hydroxychloroquine for treatment of COVID-19 began at Montefiore and Einstein
On Apr. 29, 2020, researchers at Montefiore Health System and Albert Einstein College of Medicine announced that they…
Texas A&M researchers lead testing of tuberculosis vaccine to fight COVID-19
On Apr. 29, 2020, a team of Texas A&M University researchers asked hundreds of frontline medical workers to…
INOVIO completed enrollment in phase 1 U.S. trial of INO-4800 for COVID-19 DNA vaccine
On Apr. 28, 2020, INOVIO announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800…
ViralClear submits investigational New Drug Application to FDA for phase II clinical trials for merimepodib
On Apr. 24, 2020, BioSig Technologies announced that subsidiary ViralClear had submitted an Investigational New Drug (IND) application…
Yale launched clinical trial for drug to treat severe COVID-19 patients
On Apr. 23, 2020, Yale researchers began a clinical trial at Yale New Haven Hospital to test the…
SNBL announced participation in development of a prophylactic DNA vaccine for COVID-19
On Apr. 20, 2020, SNBL announced their intention to participate in the development of a prophylactic DNA vaccine…
BioNTech and Pfizer announced regulatory approval from German authority to commence first clinical trial of COVID-19 vaccine candidates
On Apr. 22, 2020, BioNTech and Pfizer announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the…
More than 800 employees from Rutgers, Robert Wood Johnson University Hospital and University Hospital participate in a pioneering study
On Apr. 21, 2020, Rutgers University announced it has launched the nation’s largest prospective study of health care…
Immunic reported that IMU-838 demonstrated Preclinical activity against SARS-CoV-2 and explores plans for phase 2 clinical trial in COVID-19 patients
On Apr. 21, 2020, Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor successfully demonstrated…
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients
On Apr. 20, 2020, Novartis announced it had reached an agreement with the U.S. Food and Drug Administration…